453565-90-7 Usage
Uses
Used in Organic Synthesis:
3-Bromo-5-(trifluoromethoxy)Benzoicacid is used as a building block in organic synthesis for the creation of a variety of chemical compounds. Its unique functional groups allow for further chemical reactions, facilitating the development of new molecules with specific properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-Bromo-5-(trifluoromethoxy)Benzoicacid is utilized as a key intermediate for the synthesis of pharmaceutical compounds. Its presence in the molecular structure can influence the pharmacological activity, selectivity, and potency of the resulting drugs.
Used in Pharmaceutical Industry:
3-Bromo-5-(trifluoromethoxy)Benzoicacid is used as a precursor in the pharmaceutical industry for the production of drugs. Its reactivity and structural features make it suitable for the development of new therapeutic agents with improved efficacy and safety profiles.
Used in Agrochemical Industry:
3-Bromo-5-(trifluoromethoxy)Benzoicacid also finds applications in the agrochemical industry, where it serves as a starting material for the synthesis of agrochemicals such as pesticides and herbicides. Its chemical properties contribute to the effectiveness of these products in agricultural settings.
Check Digit Verification of cas no
The CAS Registry Mumber 453565-90-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,5,3,5,6 and 5 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 453565-90:
(8*4)+(7*5)+(6*3)+(5*5)+(4*6)+(3*5)+(2*9)+(1*0)=167
167 % 10 = 7
So 453565-90-7 is a valid CAS Registry Number.
453565-90-7Relevant articles and documents
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
-
, (2008/06/13)
The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
